Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly consigns shocking Xigris to critical care in investor- and state-backed biotech

This article was originally published in Scrip

Executive Summary

Lilly has decided that ten years of struggling with its sepsis drug, Xigris (drotrecogin alfa activated), is enough and now is the time to let someone else have a go. The Indianapolis-based company has licensed the US rights to the product to BioCritica, a newly formed private biotech based in central Indiana backed the private equity investors, Care Capital and NovaQuest Capital. The goal, Lilly says, is to attempt to put more resources behind US marketing of the underperforming Xigris.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013058

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel